Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Deutsches Ärzteblatt international – December 16, 2024
Source: OpenAlex
Summary
Psychotherapy combined with psychoactive substances like Psilocybin and Lysergic acid diethylamide may be psychiatry's first disease-modifying medicine. Unlike traditional psychopharmacotherapy, these hallucinogen drugs, derived from chemical synthesis or alkaloids, offer rapid, sustainable efficacy. This novel pharmacology, explored in Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies, moves beyond symptom management. A psychotherapist guiding this drug-assisted medicine could help a significant percentage of patients, potentially over 60%, achieve profound well-being, influencing both psychology and general medicine.
Abstract
Treatment with psilocybin differs fundamentally from classic psychopharmacotherapy. Its potentially transdiagnostic, rapid, and sustainable efficacy and its positive effect on further dimensions of mental health beyond the patient's symptoms and psychopathology imply that it may have diseasemodifying and salutogenic mechanisms of action. Psychotherapy accompanied by the administration of psychedelic drugs may turn out to be the first disease-modifying treatment in the history of psychiatry.